WealthShield Partners LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 15.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,510 shares of the company’s stock after acquiring an additional 478 shares during the period. WealthShield Partners LLC’s holdings in Eli Lilly and Company were worth $4,210,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Farringdon Capital Ltd. raised its holdings in shares of Eli Lilly and Company by 35.8% in the 2nd quarter. Farringdon Capital Ltd. now owns 2,549 shares of the company’s stock worth $3,057,000 after purchasing an additional 672 shares during the period. W1M Asset Management Ltd lifted its stake in Eli Lilly and Company by 405.6% in the second quarter. W1M Asset Management Ltd now owns 1,987 shares of the company’s stock valued at $2,384,000 after purchasing an additional 1,594 shares during the last quarter. Madison Wealth Partners Inc grew its holdings in Eli Lilly and Company by 26.7% during the second quarter. Madison Wealth Partners Inc now owns 1,074 shares of the company’s stock valued at $1,288,000 after purchasing an additional 226 shares during the period. X Square Capital LLC increased its position in Eli Lilly and Company by 16.2% in the second quarter. X Square Capital LLC now owns 380 shares of the company’s stock worth $456,000 after buying an additional 53 shares during the last quarter. Finally, Forum Private Client Group LLC increased its position in Eli Lilly and Company by 2.5% in the second quarter. Forum Private Client Group LLC now owns 5,577 shares of the company’s stock worth $6,690,000 after buying an additional 134 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Price Performance
LLY stock opened at $1,175.01 on Friday. The firm has a 50 day moving average of $1,187.82 and a 200-day moving average of $1,064.57. The firm has a market capitalization of $1.11 trillion, a P/E ratio of 39.43, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 12 month low of $712.05 and a 12 month high of $1,292.65. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.
Eli Lilly and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 23.22%.
Insiders Place Their Bets
In other news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last ninety days. 0.14% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Sanford C. Bernstein lifted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.
Check Out Our Latest Analysis on LLY
Eli Lilly and Company News Roundup
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Strong Zepbound real-world data: A study found that sustained Zepbound use among adults over 55 with overweight or obesity was associated with fewer hospital and emergency-room visits and lower healthcare costs. The findings could support broader payer acceptance and strengthen the case for Medicare coverage. Zepbound linked to lower healthcare costs
- Positive Sentiment: Alzheimer’s diagnostic milestone: The FDA cleared a blood test developed by Lilly and Roche to help identify Alzheimer’s-related amyloid pathology. A less-invasive test could expand access to diagnosis and support demand for Lilly’s Alzheimer’s franchise, including Kisunla. Eli Lilly clears hurdle in Alzheimer’s fight
- Positive Sentiment: Pipeline diversification: Oncology revenue increased 11% in the first half of 2026, while newer products and pipeline candidates may help Lilly reduce its dependence on GLP-1 medicines. Lilly also advanced brenipatide into a Phase 3 depression study, adding another potential long-term growth opportunity. Lilly oncology portfolio growth
- Neutral Sentiment: Valuation and positioning: Lilly remains near its 52-week high, and analysts’ median price target of approximately $1,348.50 implies additional upside. However, the elevated valuation leaves the stock vulnerable to sharp reactions when growth or reimbursement concerns emerge.
- Negative Sentiment: GLP-1 coverage concerns are weighing on sentiment: Employer-benefit surveys and reports that some companies may reduce coverage for weight-management drugs have renewed fears that payer restrictions could slow Zepbound and future oral obesity-drug adoption. The decline appears more sentiment-driven than a response to weaker operating results. GLP-1 coverage concerns
- Negative Sentiment: Cost-savings evidence has limitations: Lilly-sponsored research supports Zepbound’s medical and economic value, but critics note that the analysis measured healthcare savings before accounting for the drug’s price. This may weaken the immediate impact of the findings in payer negotiations. Lilly cost-saving study limitations
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
